Evidence map›Paper›PMID 29353626›Full record

ArticleEuropean journal of oncology nursing : the official journal of European Oncology Nursing Society2018

Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.

Christine Miaskowski, Steven M Paul, Judy Mastick, Mark Schumacher, Yvette P Conley, Betty Smoot, Gary Abrams, Kord M Kober, Steven Cheung, Jennifer Henderson-Sabes and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  8. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Christine MiaskowskiSchool of Nursing, University of California, San Francisco, CA, USA. Electronic address: chris.miaskowski@ucsf.edu.
Steven M PaulSchool of Nursing, University of California, San Francisco, CA, USA.
Judy MastickSchool of Nursing, University of California, San Francisco, CA, USA.
Mark SchumacherSchool of Medicine, University of California, San Francisco, CA, USA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
Betty SmootSchool of Medicine, University of California, San Francisco, CA, USA.
Gary AbramsSchool of Medicine, University of California, San Francisco, CA, USA.
Kord M KoberSchool of Nursing, University of California, San Francisco, CA, USA.
Steven CheungSchool of Medicine, University of California, San Francisco, CA, USA.
Jennifer Henderson-SabesSchool of Medicine, University of California, San Francisco, CA, USA.
Margaret ChesneySchool of Medicine, University of California, San Francisco, CA, USA.
Melissa MazorSchool of Nursing, University of California, San Francisco, CA, USA.
Margaret WallhagenSchool of Nursing, University of California, San Francisco, CA, USA.
Jon D LevineSchool of Medicine, University of California, San Francisco, CA, USA.
University of California, San Francisco · USUniversity of Pittsburgh · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Characterization of and Treatment for Chemotherapy NeuropathyR01CA151692 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2011 to 2015
$6.4M
Advancing the Science of Symptom Management in Oncology PatientsK05CA168960 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2013 to 2017
$453k
NCATS NIH HHS UL1 TR000004NCI NIH HHS K05 CA168960NCI NIH HHS R01 CA151692
6 · The paper itself

Abstract

purposeThe purpose of this study was to evaluate for differences in demographic, clinical, and pain characteristics, as well as measures of sensation, balance, perceived stress, symptom burden, and quality of life (QOL) among survivors who received neurotoxic chemotherapy (CTX) and who reported only chemotherapy-induced neuropathy (CIN, n = 217), CIN and hearing loss (CIN/HL, n = 69), or CIN, hearing loss, and tinnitus (CIN/HL/TIN, n = 85). We hypothesized that as the number of neurotoxicities increased, survivors would have worse outcomes.

methodsSurvivors were recruited from throughout the San Francisco Bay area. Survivors completed self-report questionnaires for pain and other symptoms, stress and QOL. Objective measures were assessed at an in person visit.

resultsCompared to survivors with only CIN, survivors with all three neurotoxicities were less likely to be female and less likely to report child care responsibilities. In addition, survivors with all three neurtoxicities had higher worst pain scores, greater loss of protective sensation, and worse timed get up and go scores. These survivors reported higher state anxiety and depression and poorer QOL. For some outcomes (e.g., longer duration of CIN, self-reported balance problems), significantly worse outcomes were found for the survivors with CIN/HL and CIN/HL/TIN compared to those with only CIN.

conclusionsOur findings suggest that compared to survivors with only CIN, survivors with CIN/HL/TIN are at increased risk for the most severe symptom burden, significant problems associated with sensory loss and changes in balance, as well as significant decrements in all aspects of QOL.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsCancer SurvivorsDepressive DisorderFemaleHearing LossHumansMaleMiddle AgedNeoplasmsNeurotoxinsPeripheral Nervous System DiseasesQuality of LifeSan FranciscoAntineoplastic AgentsNeurotoxinsBalanceChemotherapyHearing lossPeripheral neuropathySurvivorTinnitus

Identifiers

PMID29353626
PMCPMC5783195
OpenAlexW2767472616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.